VINCRISTINE SULFATE
Effects of Chemotherapy
The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Effects of Chemotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinorelbine Shi Yanxia | Phase 3 | BB |
Thalidomide China Medical University, China | Phase 3 | BB |
Lornoxicam Shi Yanxia | Phase 3 | B |
Mesna M.D. Anderson Cancer Center | Phase 2 | B |
DDP Shi Yanxia | Phase 3 | B |
EXTRINSIC PATHWAY INHIBITOR Shi Yanxia | Phase 3 | B |
Zanubrutinib The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
Polatuzumab Vedotin The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
Same molecule, other indications
VINCRISTINE SULFATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →